The possibility that approaches aimed at blocking type I IFN or their signaling pathways may provide an immunologic benefit during HIV infection is supported by animal models showing that the prolonged stimulation of pDC causes dysfunctions similar to those observed in HIV-infected patients [46,47]. The gene discussed is PDC; the disease is HIV infectious disease.